Should You Buy Adagene Inc (ADAG) Stock After it Has Risen 24.63% in a Week?

The market has been high on Adagene Inc (ADAG) stock recently. ADAG gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Adagene Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ADAG!

See Full ADAG Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ADAG Stock Today?

Adagene Inc (ADAG) stock is trading at $4.20 as of 2:53 PM on Thursday, Jan 25, an increase of $0.36, or 9.48% from the previous closing price of $3.84. The stock has traded between $3.17 and $4.25 so far today. Volume today is elevated. So far 240,005 shares have traded compared to average volume of 177,470 shares. To see InvestorsObserver's Sentiment Score for Adagene Inc click here.

More About Adagene Inc

Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline. Click Here to get the full Stock Report for Adagene Inc stock.